Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.57 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2398512 | 0.85 | CYP11B1 (0.77) | CYP11B1CYP11B2CYP17A1CYP19A1MAOB | |
| SCHEMBL28605858 | 0.85 | CYP17A1 (0.44) | CYP11B1CYP11B2CYP17A1CYP19A1MAOB | |
| SCHEMBL27429826 | 0.81 | CYP11B1 (0.55) | CYP11B1CYP11B2CYP17A1CYP19A1MAOB | |
| SCHEMBL11729224 | 0.81 | MAOB (0.79) | CYP11B1CYP11B2CYP17A1CYP19A1MAOB | |
| SCHEMBL9786551 | 0.79 | MAOB (0.46) | CYP11B1CYP11B2CYP17A1CYP19A1MAOB | |
| SCHEMBL30956074 | 0.78 | MAOB (0.45) | CYP11B1CYP11B2CYP17A1CYP19A1MAOB | |
| SCHEMBL31683144 | 0.78 | PIM1 (0.55) | CYP11B1CYP11B2CYP17A1CYP19A1MAOB | |
| SCHEMBL6511946 | 0.77 | MAOB (0.71) | CYP11B1CYP11B2CYP17A1CYP19A1MAOB | |
| SCHEMBL13298379 | 0.77 | CYP17A1 (0.40) | CYP11B1CYP11B2CYP17A1CYP19A1MAOB | |
| SCHEMBL31683120 | 0.77 | PIM1 (0.50) | CYP11B1CYP11B2CYP17A1CYP19A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016312-B2 | Animal models, screening methods, and treatment methods for intraocular diseases or disorders | Smilebiotek Zhuhai Limited (CN) | 2024-06-25 | — | — | US | disclosed |
| US-20070276138-A1 | Modulators of peroxisome proliferator activated receptors | BROOKS DAWN A | 2007-11-29 | — | — | US | disclosed |
| US-7192982-B2 | Modulators of peroxisome proliferator activated receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| EP-0731098-B1 | Alpha-substituted-3-benzyl-benzofurans | LILLY CO ELI (US) | 2003-06-18 | — | — | EP | disclosed |
| EP-0731098-B1 | Alpha-substituted-3-benzyl-benzofurans | LILLY CO ELI (US) | 2003-06-18 | — | — | EP | disclosed |
| US-5705507-A | POST-MENOPAUSAL SYNDROME | ELI LILLY AND COMPANY (US) | 1998-01-06 | — | — | US | disclosed |
| US-5705507-A | POST-MENOPAUSAL SYNDROME | ELI LILLY AND COMPANY (US) | 1998-01-06 | — | — | US | disclosed |
| US-5622974-A | POST-MENOPAUSAL SYNDROME | ELI LILLY AND COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5622974-A | POST-MENOPAUSAL SYNDROME | ELI LILLY AND COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| EP-0731098-A1 | Alpha-substituted-3-benzyl-benzofurans | ELI LILLY AND COMPANY (US) | 1996-09-11 | — | — | EP | disclosed |
| EP-0731098-A1 | Alpha-substituted-3-benzyl-benzofurans | ELI LILLY AND COMPANY (US) | 1996-09-11 | — | — | EP | disclosed |
| EP-0731098-A1 | Alpha-substituted-3-benzyl-benzofurans | ELI LILLY AND COMPANY (US) | 1996-09-11 | — | — | EP | disclosed |
| EP-0207605-B1 | HYPOGLYCEMIC THIAZOLIDINEDIONES | PFIZER INC. (US) | 1990-02-07 | — | — | EP | disclosed |
| US-4703052-A | Hypoglycemic thiazolidinediones | PFIZER INC. (US) | 1987-10-27 | — | — | US | disclosed |
| EP-0207605-A1 | Hypoglycemic thiazolidinediones | PFIZER INC. (US) | 1987-01-07 | — | — | EP | disclosed |
| WO-1986007056-A1 | HYPOGLYCEMIC THIAZOLIDINEDIONES | PFIZER INC. (US) | 1986-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12016312-B2 | Animal models, screening methods, and treatment methods for intraocular diseases or disorders | MB, MYOC, PDE6A | CYP11B1 2284/4885CYP11B2 1925/4885CYP17A1 4028/4885 |
| US-20070276138-A1 | Modulators of peroxisome proliferator activated receptors | PPARG, NCOA4, PPARA | CYP11B1 291/4885CYP11B2 218/4885CYP17A1 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.